Publicerat: 2021-06-23 08:16:30
Ahead of the Q2 report, we look for strong sales growth (Q2 sales up 60% y/y). In our view, SyntheticMR remains well positioned in the USD 4.8bn global MRI-market and we see several levers of growth throughout the year. We make minor revisions to our revenue and EBIT estimates ahead of the Q2 results, yielding an unchanged DCF-based fair value range of SEK 42-56 (previously SEK 424-559) per share following adjustment for share split (10:1).
Länk till analysen